

# Mentore Ribolsi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/48978/publications.pdf>

Version: 2024-02-01

65  
papers

2,165  
citations

218677

26  
h-index

233421

45  
g-index

65  
all docs

65  
docs citations

65  
times ranked

1483  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dilated Intercellular Spaces of Esophageal Epithelium in Nonerosive Reflux Disease Patients with Physiological Esophageal Acid Exposure. <i>American Journal of Gastroenterology</i> , 2005, 100, 543-548.	0.4	221
2	Intraoesophageal distribution and perception of acid reflux in patients with nonerosive gastrooesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 605-613.	3.7	140
3	Nutritional Aspects in Inflammatory Bowel Diseases. <i>Nutrients</i> , 2020, 12, 372.	4.1	127
4	Dynamic contrast enhanced magnetic resonance imaging of the terminal ileum: differentiation of activity of Crohn's disease. <i>Abdominal Imaging</i> , 2008, 33, 417-424.	2.0	114
5	Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with nonerosive gastrooesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 629-636.	3.7	107
6	Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. <i>Gut</i> , 2007, 57, 443-447.	12.1	100
7	Weak Peristalsis With Large Breaks Is Associated With Higher Acid Exposure and Delayed Reflux Clearance in the Supine Position in GERD Patients. <i>American Journal of Gastroenterology</i> , 2014, 109, 46-51.	0.4	85
8	Practice guidelines on the use of esophageal manometry – A GISMAD-SIGE-AIGO medical position statement. <i>Digestive and Liver Disease</i> , 2016, 48, 1124-1135.	0.9	82
9	Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 6529.	3.3	64
10	Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 966-973.	3.7	63
11	Effect of endoscopic augmentation of the lower oesophageal sphincter (Gatekeeper reflux repair) Tj ETQq1 1 0.784314 rgBT /Overl	12.1	60
12	Role of Overweight and Obesity in Gastrointestinal Disease. <i>Nutrients</i> , 2020, 12, 111.	4.1	59
13	Relationship between baseline impedance levels and esophageal mucosal integrity in children with erosive and nonerosive reflux disease. <i>Neurogastroenterology and Motility</i> , 2012, 24, 828.	3.0	53
14	Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. <i>Gut</i> , 2021, 70, 1441-1449.	12.1	49
15	Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1063-1071.	3.7	48
16	Effect of hiatal hernia on proximal oesophageal acid clearance in gastro-oesophageal reflux disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 751-757.	3.7	46
17	Regional oesophageal sensitivity to acid and weakly acidic reflux in patients with nonerosive reflux disease. <i>Neurogastroenterology and Motility</i> , 2009, 21, 253-258.	3.0	46
18	Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastrooesophageal reflux disease according to Lyon Consensus. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 412-418.	3.7	42

#	ARTICLE	IF	CITATIONS
19	Characteristics of the Esophageal Low-Pressure Zone in Healthy Volunteers and Patients With Esophageal Symptoms: Assessment by High-Resolution Manometry. <i>American Journal of Gastroenterology</i> , 2008, 103, 2544-2549.	0.4	41
20	Impedance baseline and reflux perception in responder and non-responder non-erosive reflux disease patients. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1266-1273.	1.5	32
21	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1074-1081.	3.7	32
22	Fragmented and failed swallows on esophageal high-resolution manometry associate with abnormal reflux burden better than weak swallows. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13736.	3.0	32
23	Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters. <i>Gut</i> , 2022, 71, 1062-1067.	12.1	32
24	Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors. <i>Digestive and Liver Disease</i> , 2012, 44, 549-554.	0.9	30
25	Intercellular space diameters of the oesophageal epithelium in NERD patients: Head to head comparison between light and electron microscopy analysis. <i>Digestive and Liver Disease</i> , 2009, 41, 9-14.	0.9	28
26	Diagnostic delay and misdiagnosis in eosinophilic oesophagitis. <i>Digestive and Liver Disease</i> , 2021, 53, 1632-1639.	0.9	28
27	Impedance-High Resolution Manometry Analysis of Patients With Nonerosive Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 52-57.	4.4	27
28	Correlation between reflux burden, peristaltic function, and mucosal integrity in GERD patients. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13752.	3.0	27
29	The Lyon Consensus: Does It Differ From the Previous Ones?. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 311-321.	2.4	26
30	Applying Lyon Consensus criteria in the workup of patients with proton pump inhibitory-refractory heartburn. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1423-1430.	3.7	24
31	Palmitic Acid Affects Intestinal Epithelial Barrier Integrity and Permeability In Vitro. <i>Antioxidants</i> , 2020, 9, 417.	5.1	23
32	Platelet-activating factor and distinct chemokines are elevated in mucosal biopsies of erosive compared with non-erosive reflux disease patients and controls. <i>Neurogastroenterology and Motility</i> , 2012, 24, 943.	3.0	22
33	Post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance predict PPI response in GERD patients with extra esophageal symptoms. <i>Digestive and Liver Disease</i> , 2020, 52, 173-177.	0.9	22
34	Esophageal pH increments associated with post-reflux swallow-induced peristaltic waves show the occurrence and relevance of esophago-salivary reflex in clinical setting. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14085.	3.0	20
35	High-resolution Manometry Determinants of Refractoriness of Reflux Symptoms to Proton Pump Inhibitor Therapy. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 447-454.	2.4	19
36	Effect of oesophagitis on proximal extent of gastro-oesophageal reflux. <i>Neurogastroenterology and Motility</i> , 2007, 19, 459-464.	3.0	15

#	ARTICLE	IF	CITATIONS
37	Acid reflux episodes sensitize the esophagus to perception of weakly acidic and mixed reflux in non-erosive reflux disease patients. <i>Neurogastroenterology and Motility</i> , 2014, 26, 108-114.	3.0	15
38	Association between Dietary Habits and Fecal Microbiota Composition in Irritable Bowel Syndrome Patients: A Pilot Study. <i>Nutrients</i> , 2021, 13, 1479.	4.1	15
39	Role of Mixed Reflux and Hypomotility with Delayed Reflux Clearance in Patients with Non-cardiac Chest Pain. <i>Journal of Neurogastroenterology and Motility</i> , 2016, 22, 606-612.	2.4	14
40	Postreflux swallow-induced peristaltic wave index from pH-impedance monitoring associates with esophageal body motility and esophageal acid burden. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13973.	3.0	14
41	The Results From Up-Front Esophageal Testing Predict Proton Pump Inhibitor Response in Patients With Chronic Cough. <i>American Journal of Gastroenterology</i> , 2021, 116, 2199-2206.	0.4	14
42	Oesophageal mucosal intercellular space diameter and reflux pattern in childhood erosive and non-erosive reflux disease. <i>Digestive and Liver Disease</i> , 2012, 44, 981-987.	0.9	13
43	Dilated intercellular space diameter as marker of reflux-related mucosal injury in children with chronic cough and gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 733-742.	3.7	13
44	New classifications of gastroesophageal reflux disease: an improvement for patient management?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 761-769.	3.0	11
45	High-resolution Manometry Findings During Solid Swallows Correlate With Delayed Reflux Clearance and Acid Exposure Time in Non-erosive Reflux Disease Patients. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 68-74.	2.4	11
46	Reflux characteristics triggering post-reflux swallow-induced peristaltic wave (PSPW) in patients with GERD symptoms. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14183.	3.0	10
47	Patients With Definite and Inconclusive Evidence of Reflux According to Lyon Consensus Display Similar Motility and Esophagogastric Junction Characteristics. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 565-573.	2.4	7
48	Impaired Colonic Contractility and Intestinal Permeability in Symptomatic Uncomplicated Diverticular Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 292-301.	2.4	6
49	Baseline Impedance Levels and Structural and Functional Integrity of the Esophageal Mucosa: Is Acid Still the Only Player?. <i>American Journal of Gastroenterology</i> , 2012, 107, 1104.	0.4	5
50	Role of Esophageal Motility, Acid Reflux, and of Acid Suppression in Nonobstructive Dysphagia. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 607-613.	2.2	4
51	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, , 1-10.	3.0	4
52	Association between post-reflux swallow-induced peristaltic wave index and esophageal mucosal integrity in patients with GERD symptoms. <i>Neurogastroenterology and Motility</i> , 2023, 35, e14344.	3.0	4
53	Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis. <i>Current Opinion in Pharmacology</i> , 2022, 65, 102264.	3.5	4
54	Understanding the relationship between esophageal motor disorders and reflux disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 933-940.	3.0	3

#	ARTICLE	IF	CITATIONS
55	Editorial: inconclusive diagnosis of GERD: are new parameters in impedance-pHmetry ready for clinical use? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 498-499.	3.7	2
56	Exploring the association between esophageal mucosal inflammation, impaired motility, and GERD severity. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14211.	3.0	2
57	Nonachalasic esophageal motor disorders, from diagnosis to therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 205-216.	3.0	2
58	Letter: the potential link between oesophageal hypervigilance, visceral anxiety, increased swallow rate and oesophageal mucosal integrity. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 756-757.	3.7	2
59	Relevance of Excessive Air Swallowing in GERD Patients With Concomitant Functional Dyspepsia and Poor Response to PPI Therapy. <i>Journal of Clinical Gastroenterology</i> , 2023, 57, 466-471.	2.2	2
60	Measurement of acid exposure of proximal esophagus: a better tool for diagnosing non-erosive reflux disease. <i>Neurogastroenterology and Motility</i> , 2011, 23, 711-e324.	3.0	1
61	Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 974-975.	3.7	1
62	Reply. <i>Gastroenterology</i> , 2015, 148, 1067.	1.3	0
63	Clinical impact of proton pump inhibitor response and dependence. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13846.	3.0	0
64	Letter to the Editor: Relevance of a Correct GERD Patient Classification Before Anti-reflux Procedures. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 721-722.	1.7	0
65	Editorial: Lyon consensus metrics towards personalised diagnosis of non-erosive reflux disease: Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1216-1217.	3.7	0